Biomarker-driven medical research involving adults who have or are at risk of developing cancer
1400+ member research sites
Joined November 2013
- Tweets9.6K
- Following2.5K
- Followers6.7K
- Likes3.9K
Pinned Tweet
Congratulations to Dr. Bob Gray of @HarvardChanSPH @DanaFarber on his retirement as @eaonc Group Statistician! 🎉 We’re grateful for his many contributions to the #CancerResearch community. Wishing him all the best in this next chapter!
ECOG-ACRIN Cancer Research Group retweeted
It was an honor to present at The Robert L. Comis, MD Translational Science Symposium on the role that inflammation plays in tumorigenesis with the aim to find targets for cancer prevention and interception. Thanks ECOG-ACRIN cancer research group for this incredible opportunity.
The Robert L. Comis, MD #TranslationalScience Symposium has begun with great talks on "#Inflammation as a Shared Mechanism Across Diseases" by @MoghaddamSeyed & @humam_kadara of @UTMDAnderson & @tonyrcillo of @UPMCHillmanCC #eaonc
ECOG-ACRIN Cancer Research Group retweeted
Proud of our @SylvesterCancer trainees named Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars at the @eaonc Meeting in Philadelphia! 🎉 Congrats to our hem-onc fellow @dan_morgen and rad-onc residents @belladreyfuss25 & @xlabissieremd.
#HemOnc #RadOnc #HealthEquity #ClinicalTrials
Congratulations to the Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars: Kamryn Clay, @belladreyfuss25, Dr. Ekpenyong, Dr. Gabra, Alaina Hawkins, @xlabissieremd, @dan_morgen, @PhyuNaing4, @OgaKingsley, & Kennedy Stacy #CancerResearch #ClinicalTrials #eaonc
ECOG-ACRIN Cancer Research Group retweeted
Grateful to @eaonc for the opportunity to present our research and for selecting me among the Young Investigator Award recipients for an oral presentation at the Fall meeting!
🧬🫁 I shared our findings from 14,246 patients with NSCLC, highlighting how the genomic drivers and tumor immune landscape differ across age groups, with important implications for precision oncology.
Thankful to my mentor @GlopesMd @SylvesterCancer and all our collaborators for their continued support! @Latinamd @Labcorp @NarjustFlorezMD @DionysiosWatson @DesaiP_Oncdoc
ECOG-ACRIN Cancer Research Group retweeted
That is a serious group on that stage. Collaborative groups like ECOG-ACRIN are where practice-changing trials actually get done. I'd have loved to be in the room for this one. Kudos for pulling them together. #CancerResearch
A very Philadelphia General Session at our Fall 2026 Group Meeting. Delighted to be joined by @AACR_CEO of @AACR and Cancer Center Directors Dr. Vonderheide of @PennCancer, Dr. Chapman of @KimmelCancerCtr & @DrRobWinn of @FoxChaseCancer! #CancerResearch
ECOG-ACRIN Cancer Research Group retweeted
Enjoyed the opportunity to present our work developing an AI-powered novel histopathologic biomarker in early-stage NSCLC at the @eaonc Data Science Committee meeting.
Thank you for the invitation @ValsamoA!
#LCSM #DigitalPathology #LungCancer
@CharuAggarwalMD @valarlabs
ECOG-ACRIN Cancer Research Group retweeted
Fantastic fall 2026 @eaonc meeting! Great to connect with colleagues nationwide and brainstorm on concepts in development. Honored to take on a leadership role within the Kidney Cancer Subcommittee as Chair for community - helping broaden access to kidney cancer research.
ECOG-ACRIN Cancer Research Group retweeted
Congrats @jordanberlin5 , what an outstanding honor! We surgeons very much appreciate your guidance and the wisdom you share, often and always! @eaonc
Congrats to 🌟 @jordanberlin5 for winning the @eaonc #Mentor of the Year Award! 👏👏👏 Well deserved!!!! He received a standing ovation!! @VUMCDiscoveries
Do you have newly diagnosed #MultipleMyeloma and are either ineligible for or willing to delay #StemCell transplantation? If so, you may be eligible to participate in #ClinicalTrial EAA181/EQUATE. More info here: bit.ly/eaa181equate #MMSM #NDMM cc: @MM_Hub, @theMMRF
.@MonikaJoshimd and @PGrivasMDPhD are leading #ClinicalTrial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced #UrothelialCancer. bit.ly/ea8231-study
Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back after initial therapy. Learn more: bit.ly/ea3191-study #HeadAndNeckCancer #HNCA
ECOG-ACRIN Cancer Research Group retweeted
Very interesting and pertains to myeloma even more.
Dr. Mark Rocschewski @MSKCancerCenter presenting at @eaonc Heme Malignancy session showed this interesting slide pertaining to large cell lymphoma.
Patients who clear circulating tumor DNA of course do well. But what’s interesting is 25% of patients with detectable circulating tumor DNA have no recurrence. A real plateau!
Residual ctDNA (or MRD) may not necessarily mean bad outcome.
Do you have early-stage #melanoma and are age 75 or older? If so, you may be eligible to participate in this study of a potential new treatment approach. More info: bit.ly/ea6244-study #SkinCancer #MelanomaResearch
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer | EA2251 will be led by Deirdre Cohen @TischCancer and supported by @theNCI and @SMMT_TX
ecog-acrin.org/press-release… – at Philadelphia, PA
ECOG-ACRIN Cancer Research Group retweeted
Respect to amazing legend in biostatistics Bob Gray who has transformed the field of biostatistics with huge impact in oncology globally! Wonderful to see #NancyDavidson @fredhutch @jsparano @AACRPres & others commenting on his career! Congrats on retirement!
@eaonc
@VincentRK
Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH
ECOG-ACRIN Cancer Research Group retweeted
Fantastic to watch @eaonc general session with amazing speakers @AACR_CEO & other leaders sitting next to @VincentRK who has transformed the field in multiple myeloma! Always inspired to be with global leaders as we work together to create vision & move field forward @OncoAlert
ECOG-ACRIN Cancer Research Group retweeted
My colleague @myelomaMD is presenting the results of the ENDURANCE randomized trial at General Session of ECOG-ACRIN group meeting. This trial showed 2 years of lenalidomide maintenance provides same survival as indefinite maintenance in standard risk myeloma. @eaonc @NEJM
A very Philadelphia General Session at our Fall 2026 Group Meeting. Delighted to be joined by @AACR_CEO of @AACR and Cancer Center Directors Dr. Vonderheide of @PennCancer, Dr. Chapman of @KimmelCancerCtr & @DrRobWinn of @FoxChaseCancer! #CancerResearch